Emma C. Morris

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 102 publications

Vancomycin disrupts mitochondrial morphology and function and impairs macrophage fungal killing.

Vancomycin disrupts mitochondrial morphology and function and impairs macrophage fungal killing.

Journal: mBio

Published: April 29, 2026

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Journal: Bone marrow transplantation

Published: April 26, 2026

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Journal: Cancers

Published: February 26, 2026

Organ-specific phenotypes of Candida albicans: implications for immunity and pathogenesis.

Organ-specific phenotypes of Candida albicans: implications for immunity and pathogenesis.

Journal: Current opinion in microbiology

Published: February 20, 2026

Incomplete T-cell tolerance and epitope-specific responses to the NR1 subunit in NMDA receptor antibody-associated encephalitis.

Incomplete T-cell tolerance and epitope-specific responses to the NR1 subunit in NMDA receptor antibody-associated encephalitis.

Journal: Brain communications

Published: December 12, 2025

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Journal: The New England journal of medicine

Published: December 08, 2025

High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Journal: Cancers

Published: November 26, 2025

Updated EBMT/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism.

Updated EBMT/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism.

Journal: Bone marrow transplantation

Published: November 16, 2025

Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing.

Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing.

Journal: Blood

Published: October 28, 2025

Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging.

Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging.

Journal: Journal of human immunity

Published: October 27, 2025

The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.

The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.

Journal: Frontiers in immunology

Published: October 02, 2025

Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro.

Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro.

Journal: Immunotherapy advances

Published: August 06, 2025

Showing 1-12 of 102

Last Updated: 09/26/2026